Leticia Leone Lauricella

Leticia Leone Lauricella

Auto-generated profile, based on publicly available information

Leticia Leone Lauricella

Universidade de São Paulo, Brasil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
RTRicardo Mingarini Terra1A
Ricardo Mingarini Terra1A
PAPedro Henrique Xavier Nabuco de Araujo1A
Pedro Henrique Xavier Nabuco de Araujo1A
LLLeticia Leone Lauricella1A
Leticia Leone Lauricella1A
JCJose Ribas Milanese de Campos1A
Jose Ribas Milanese de Campos1A
JTJuliana Rocha Mol Trindade1A
Juliana Rocha Mol Trindade1A
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Objective: To compare 90-day morbidity in patients undergoing lung lobectomy performed by either robotic-assisted thoracic surgery (RATS) or video-assisted thoracic surgery (VATS). Intraoperative complications, drainage time, length of hospital stay, postoperative pain, postoperative quality of life, and readmissions within 90 days were also compared. Methods: This was a two-arm randomized clinical trial including patients with lung lesions (primary lung cancer or lung metastasis) who were candidates for lung lobectomy. Patients with comorbidities that precluded surgical treatment were excluded. All patients followed the same postoperative protocol. Results: The overall sample comprised 76 patients (39 in the VATS group and 37 in the RATS group). The two groups were similar regarding gender, age, BMI, FEV1 in % of predicted, and comorbidities. Postoperative complications within 90 days tended to be more common in the VATS group than in the RATS group, but the difference was not significant (p = 0.12). However, when only major complications were analyzed, this tendency disappeared (p = 0.58). Regarding postoperative outcomes, the VATS group had a significantly higher number of readmissions within 90 days than did the RATS group (p = 0.029). No significant differences were found regarding intraoperative complications, drainage time, length of hospital stay, postoperative pain, and postoperative quality of life. Conclusions: RATS and VATS lobectomy had similar 90-day outcomes. However, RATS lobectomy was associated with a significant reduction in the 90-day hospital readmission rate. Larger studies are necessary to confirm such a finding. (ClinicalTrials.gov identifier: NCT02292914 [http://www.clinicaltrials.gov/])

18 June 2021 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
GHGuilherme Harada
Guilherme Harada
MNMaria Fernanda Batistuzzo Vicentini Neffa
Maria Fernanda Batistuzzo Vicentini Neffa
RBRenata Colombo Bonadio
Renata Colombo Bonadio
EMElizabeth Zambrano Mendoza
Elizabeth Zambrano Mendoza
RCRafael Caparica
Rafael Caparica
GJGilberto De Castro Jr
Gilberto De Castro Jr
Objective: Adjuvant chemotherapy (AC) improves survival of patients with resected non-small cell lung cancer (NSCLC). However, the cisplatin-vinorelbine regimen has been associated with a significant risk of clinically relevant toxicity. We sought to evaluate the effectiveness, safety, and feasibility of AC for NSCLC patients in a real-world setting. Methods: This was a single-center, retrospective cohort study of patients with stage I-III NSCLC undergoing surgery with curative intent between 2009 and 2018. AC was administered at the discretion of physicians. The patients were divided into two groups: AC group and no AC (control) group. Study outcomes included overall survival (OS) and recurrence-free survival (RFS), as well as the safety profile and feasibility of the cisplatin-vinorelbine regimen in a real-world setting. Results: The study involved 231 patients, 80 of whom received AC. Of those, 55 patients received the cisplatin- vinorelbine regimen. Survival analyses stratified by tumor stage showed that patients with stage II NSCLC in the AC group had better RFS (p = 0.036) and OS (p = 0.017) than did those in the no AC group. Among patients with stage III NSCLC in the AC group, RFS was better (p < 0.001) and there was a trend toward improved OS (p = 0.060) in comparison with controls. Of those who received the cisplatin- vinorelbine regimen, 29% had grade 3-4 febrile neutropenia, and 9% died of toxicity. Conclusions: These results support the benefit of AC for NSCLC patients in a real-world setting. However, because the cisplatin-vinorelbine regimen was associated with alarming rates of toxicity, more effective and less toxic alternatives should be investigated.

1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
BBBenoit Jacques Bibas
Benoit Jacques Bibas
RCRafael Lucas Costa-De-Carvalho
Rafael Lucas Costa-De-Carvalho
FPFlavio Pola-Dos-Reis
Flavio Pola-Dos-Reis
LLLeticia Leone Lauricella
Leticia Leone Lauricella
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
RTRicardo Mingarini Terra
Ricardo Mingarini Terra

1 January 2020 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
RTRicardo Mingarini Terra
Ricardo Mingarini Terra
BBBenoit Jacques Bibas
Benoit Jacques Bibas
RHRui Haddad
Rui Haddad
JMJosé Ribas Milanez-De-Campos
José Ribas Milanez-De-Campos
PNPedro Henrique Xavier Nabuco-De-Araujo
Pedro Henrique Xavier Nabuco-De-Araujo
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Objective: To describe the morbidity, mortality, and rate of complete resection associated with robotic surgery for the treatment of non-small cell lung cancer in Brazil, as well as to report the rates of overall survival and disease-free survival in patients so treated. Methods: This was a retrospective study of patients diagnosed with non-small cell lung carcinoma and undergoing resection by robotic surgery at one of six hospitals in Brazil between February of 2015 and July of 2018. Data were collected retrospectively from the electronic medical records. Results: A total of 154 patients were included. The mean age was 65 ± 9.5 years (range, 30-85 years). The main histological diagnosis was adenocarcinoma, which was identified in 128 patients (81.5%), followed by epidermoid carcinoma, identified in 14 (9.0%). Lobectomy was performed in 133 patients (86.3%), and segmentectomy was performed in 21 (13.7%). The mean operative time was 209 ± 80 min. Postoperative complications occurred in 32 patients (20.4%). The main complication was air leak, which occurred in 15 patients (9.5%). The median (interquartile range) values for hospital stay and drainage time were 4 days (3-6 days) and 2 days (2-4 days), respectively. There was one death in the immediate postoperative period (30-day mortality rate, 0.5%). The mean follow-up period was 326 ± 274 days (range, 3-1,110 days). Complete resection was achieved in 97.4% of the cases. Overall mortality was 1.5% (3 deaths), and overall survival was 97.5%. Conclusions: Robotic pulmonary resection proved to be a safe treatment for lung cancer. Longer follow-up periods are required in order to assess long-term survival.

1 January 2020 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
RTRicardo Mingarini Terra
Ricardo Mingarini Terra
JMJosé Ribas Milanez-De-Campos
José Ribas Milanez-De-Campos
RHRui Haddad
Rui Haddad
JTJuliana Rocha Mol Trindade
Juliana Rocha Mol Trindade
LLLeticia Leone Lauricella
Leticia Leone Lauricella
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Objective: To evaluate the results of resection of tumors of the thymus by robotic thoracic surgery, analyzing the extent of resection, postoperative complications, time of surgery, and length of stay. Methods: Retrospective study from a database involving patients diagnosed with a tumor of the thymus and undergoing robotic thoracic surgery at one of seven hospitals in Brazil between October of 2015 and June of 2018. Results: During the study period, there were 18 cases of resection of tumors of the thymus: thymoma, in 12; carcinoma, in 2; and carcinoid tumor, in 1; high-grade sarcoma, in 1; teratoma, in 1; and thymolipoma, in 1. The mean lesion size was 60.1 ± 32.0 mm. Tumors of the thymus were resected with tumor-free margins in 17 cases. The median (interquartile range) for pleural drain time and hospital stay, in days, was 1 (1-3) and 2 (2-4), respectively. There was no need for surgical conversion, and there were no major complications. Conclusions: Robotic thoracic surgery for resection of tumors of the thymus has been shown to be feasible and safe, with a low risk of complications and with postoperative outcomes comparable to those of other techniques.

14 March 2024 in Clinics
Verified
Journal Article
Open access
FMFabio Minamoto
Fabio Minamoto
PAPedro Araújo
Pedro Araújo
PDPaula D'AMbrosio
Paula D'AMbrosio
AVAlberto Dela Vega
Alberto Dela Vega
LLLeticia Lauricella
Leticia Lauricella
RTRicardo Terra
Ricardo Terra
Lung lymphatic drainage occurs mainly through a peribronchial path, but it is hypothesized that visceral pleural invasion could alter this path. This study aims to investigate the association between visceral pleural invasion, node upstaging, and N2 skip metastasis and the impact on survival in a population of patients with non-small cell lung cancer of 3 cm or smaller. We retrospectively queried our institutional database of lung cancer resection for all patients with clinical stage IA NSCLC between June 2009 and June 2022. We collected baseline characteristics and clinical and pathological staging data. Patients were classified into two groups: The non-VPI group with negative visceral pleural invasion and the VPI group with positive. The primary results analyzed were the occurrence of nodal upstaging, skip N2 metastasis and recurrence. There were 320 patients analyzed. 61.3 % were women; the median age was 65.4 years. The pleural invasion occurred in 44 patients (13.7 %). VPI group had larger nodules (2.3 vs. 1.7 cm; p < 0.0001), higher 18F-FDG uptake (7.4 vs. 3.4; p < 0.0001), and lymph-vascular invasion (35.7 % vs. 13.5 %, p = 0.001). Also, the VPI group had more nodal disease (25.6 % vs. 8.7 %; p = 0.001) and skip N2 metastasis (9.3 % vs. 1.8 %; p = 0.006). VPI was a statistically independent factor for skip N2 metastasis. Recurrence occurred in 17.2 % of the population. 5-year disease-free and overall survival were worse in the VPI group. The visceral pleural invasion was an independent factor associated with N2 skip metastasis and had worse disease-free and overall survival.